Research Analysts Set Expectations for CervoMed Q4 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Analysts at HC Wainwright issued their Q4 2024 earnings estimates for CervoMed in a research note issued to investors on Thursday, December 5th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for CervoMed’s Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.87) EPS.

Other equities analysts also recently issued research reports about the stock. Roth Mkm started coverage on shares of CervoMed in a research report on Friday. They set a “buy” rating and a $45.00 price objective for the company. D. Boral Capital reissued a “buy” rating and set a $34.00 price target on shares of CervoMed in a report on Wednesday, November 27th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of CervoMed in a report on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $48.63.

CervoMed Stock Up 22.5 %

Shares of NASDAQ CRVO opened at $11.91 on Friday. The stock has a fifty day moving average price of $12.07 and a 200 day moving average price of $15.09. CervoMed has a 1-year low of $5.85 and a 1-year high of $26.38.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The company had revenue of $1.94 million for the quarter, compared to analyst estimates of $1.75 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in shares of CervoMed by 5.2% during the 2nd quarter. Renaissance Technologies LLC now owns 32,333 shares of the company’s stock worth $554,000 after acquiring an additional 1,600 shares in the last quarter. Fred Alger Management LLC acquired a new position in CervoMed during the second quarter worth $60,000. Citizens Financial Group Inc. RI boosted its position in CervoMed by 13.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock worth $445,000 after purchasing an additional 3,553 shares in the last quarter. FMR LLC acquired a new stake in CervoMed in the third quarter valued at $56,000. Finally, Rhumbline Advisers acquired a new stake in CervoMed in the second quarter valued at $96,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.